Theravance (THRX) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Theravance Reports Second Quarter 2015 Financial Results
July 29, 2015 4:06 PM EDTSOUTH SAN FRANCISCO, CA -- (Marketwired) -- 07/29/15 -- Theravance, Inc. (NASDAQ: THRX) today reported financial results for the second quarter ended June 30, 2015. Royalties from sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA earned from Glaxo Group Limited (GSK) during the second quarter of 2015 were $13.9 million, a quarter-over-quarter increase of 37 percent compared to the first quarter of 2015. Income from operations increased to $5.1 million, compared to $0.7 million in the first quarter, while adjusted EBITDA for the second quarter of 2015 was $10.4 million. Net loss for the second quarter 2015 was $7.8 million or $0.07 per share. Cash and cash equivalents, short-term investments, and... More
